OnKure ups R&D spending as it gears up for FDA apps
OnKure Therapeutics Inc. (Nasdaq: OKUR), a Boulder precision-oncology company that went public in 2024 via a merger with California-based Reneo Pharmaceuticals Inc., increased its expenses and net loss in the third quarter as it prepares to submit key findings about several drug candidates to regulators.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
OnKure boosted its research and development spending in the second quarter as trials for breast…
-
GREELEY — The Greeley City Council voted Tuesday night to file a lawsuit against Duran…
-
Quish & Co. LLC, a Boulder-based wealth-management firm, has been acquired by Sequoia Financial Group…
-
Arsenal Health LLC, which describes itself as an “integrated health optimization company,” is seeking incentives…
